We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit. Children with ...
A Central Valley single mother is facing an uphill battle to save her 4-year-old daughter from a rare disease that could ...
This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...
A 45-year-old lady, originally from Surinam, presented with a 3 year history of epiphora and irritation of both eyes. There was no other relevant past medical or family history. Visual acuity was ...
NEUROFIBROMATOSIS is a congenital and hereditary disorder involving ectodermal, neuroectodermal and mesodermal tissue. Café-au-lait spots, cutaneous neurofibromas, tumors of the central and peripheral ...
GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results